Transforming therapeutics to make a difference in patient health

Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas.

AmacaThera’s Sci­ence

Grounded in the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, we’re developing products at the intersection of biomaterials and pharmaceuticals.

Yellow Needles

Our Team

We’ve brought together commercial leaders, researchers and biotechnology experts that will transform therapeutics development while making a difference in patient outcomes.

Team

Recent News

AmacaThera Doses First Subjects in Phase 1 Clinical Trial for AmacaGel™ Therapeutic Platform

   Press Release

AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more

AmacaThera’s Lung Cancer Applications Recognized in QuickFire Challenge

   Press Release

AmacaThera has received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma.Read more

How AMT-143 could reduce the post-surgical need for opioids

   Press Release

In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a 35-second animation. Watch the animated explainer inside this article.Read more

Amacathera Logo

AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.

Contact Us

416-360-2094
MaRS Centre, West Tower,
661 University Ave Suite 1300,
Toronto, ON M5G 0B7

[email protected]